STUDIES OF NATURALLY OCCURRING DEFECTS IN RESISTANCE TO INFECTION

天然存在的抗感染缺陷的研究

• 批准号: 7603419
• 负责人: HANS D OCHS
• 金额: $ 0.01万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603419
• 关键词: Antibodies; Antibody Formation; Antigens; Bacteriophages; Blood specimen; Bone Marrow Transplantation; Childhood; Computer Retrieval of Information on Scientific Projects Database; Consent; Defect; Diagnostic; Funding; Grant; Immune; Immune response; Immune system; Immunization; Immunoglobulin Class Switching; Immunoglobulin M; Immunoglobulin Somatic Hypermutation; Immunoglobulin Switch Recombination; Immunoglobulin Therapy; Immunoglobulins; Immunologic Deficiency Syndromes; Individual; Infusion procedures; Injection of therapeutic agent; Institution; Intravenous; Intravenous Immunoglobulins; Investigation; Marrow; Measures; Numbers; Patients; Protocols documentation; Purpose; Research; Research Personnel; Resistance to infection; Resources; Route; Source; Standards of Weights and Measures; T-Lymphocyte; Time; United States Food and Drug Administration; United States National Institutes of Health; Week; reconstitution; response; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this ongoing study is to evaluate the immune status of patients with primary immunodeficiency disorders. One aspect of this investigation, and the only subject of this application, is to measure the antibody responses to the T cell-dependent neoantigen, Bacteriophage phiX174, which allows assessment of antigen clearance, the primary IgM response and the secondary response that determines amplification, class switch recombination and somatic hypermutation. Use of Bacteriophage is, in most instances, diagnostic and rarely research. Since Bacteriophage is controlled by the FDA and has an IND number, we need to obtain consent from all patients independent of its use as a diagnostic tool or as a research tool. The response to Bacteriophage will help us to determine the need for immunoglobulin therapy or, in some cases, for bone marrow transplantation (BMT). Following successful BMT, Bacteriophage phiX174 immunization may be used to determine if the marrow recipient's immune system has been fully reconstituted and if it is safe to give standard childhood immunizations. To assess a "mature" immune response to this T cell-dependent antigen, each patient is immunized with a primary injection followed by booster injections (up to three or four times) with this antigen by the intravenous route. This antigen is especially useful in individuals on IVIG because recall antigens cannot be used if an individual receives immunoglobulin infusions. Our standard protocol requests that samples of blood are obtained for antibody analysis at one, two and four weeks post immunization.

这个子项目是众多研究子项目之一